Skip to main content
. 2019 Apr 12;10(28):2709–2721. doi: 10.18632/oncotarget.26831

Figure 6. Aplidin decreases tumor growth and inhibits bone resorption in an ex vivo bone organ model of multiple myeloma.

Figure 6

The levels of the tumor growth marker IgG2b and the bone resorption marker CTX were evaluated in conditioned media collected from control bones and bones bearing 5TGM1 MM cells. (A) Bright field pictures show the piece of calvarial bone and GFP fluorescent images show 5TGM1-GFP MM cells within the bone. Bones bearing MM cells were cultured with/without Aplidin alone (B) or combined with Dex and Btz (C). IgG2b and CTX levels were determined after 3 days. Percent change was calculated over bones bearing MM cells and cultured under vehicle conditions. Combined results of two independent ex vivo studies are shown. 4-6 independent calvarial bones were used per condition/experiment. Bars represent means ± SD. *p < 0.05 vs MM-veh; lines indicate p values < 0.05 comparing MM-Dex/Btz alone vs MM-Dex/Btz + Aplidin.